Investor Relations

A leadership story in the field of advanced cell therapy

Investor Relations

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Vericel to Host Analyst and Investor Day on April 11, 2018
CAMBRIDGE, Mass. , March 12, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that it will host an Analyst and Investor Day on April 11, 2018 in New York City from 8:30 a.m.
View HTML
Toggle Summary Vericel to Present at BioCentury’s 25th Annual Future Leaders in the Biotech Industry Conference
CAMBRIDGE, Mass. , March 09, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Gerard Michel , chief financial officer and VP of corporate development, will present the latest
View HTML
Toggle Summary Vericel Reports Fourth Quarter and Year End 2017 Financial Results and Provides Full Year 2018 Financial Guidance
Record Quarterly Revenues of $23.4 Million Represent a 41% Increase Over Fourth Quarter 2016 Positive Operating and Net Income Reported for the Fourth Quarter Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass. , March 05, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a
View HTML
Toggle Summary World Champion Swimmer and Twelve-Time Medalist Dara Torres Partners with Vericel for the ‘It’s Your Move’ Campaign
Campaign Aims to Empower Patients with Knee Pain to Seek Treatment CAMBRIDGE, Mass. , March 05, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that world champion swimmer,
View HTML
Toggle Summary Vericel to Present at the 13th Annual Canaccord Genuity Musculoskeletal Conference
CAMBRIDGE, Mass. , Feb. 26, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo , president and CEO, will present the latest company overview at the 13th Annual
View HTML
Toggle Summary Vericel to Report Fourth-Quarter and Full-Year 2017 Financial Results on March 5, 2018
CAMBRIDGE, Mass. , Feb. 22, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its fourth-quarter and full-year 2017 financial
View HTML
Toggle Summary Vericel to Present at the BIO CEO & Investor Conference
CAMBRIDGE, Mass. , Feb. 05, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo , president and CEO, will present the latest company overview at the BIO CEO &
View HTML
Toggle Summary Vericel to Present at the 7th Annual Leerink Partners Global Healthcare Conference
CAMBRIDGE, Mass. , Feb. 01, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo , president and CEO, will present the latest company overview at the 7 th Annual
View HTML
Toggle Summary Vericel to Present at the 20th Annual Needham Growth Conference
CAMBRIDGE, Mass. , Jan. 10, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo , president and CEO, will present the latest
View HTML
Toggle Summary Vericel Initiates Collaboration with Innovative Cellular Therapeutics
CAMBRIDGE, Mass. and SHANGHAI, China, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced the initiation of its License Agreement with
View HTML

Day High:
Day Low:
Volume:
on
Copyright West LLC. Minimum 15 minutes delayed.